Somewhat Positive Press Coverage Somewhat Unlikely to Affect Beyondspring (BYSI) Share Price

Press coverage about Beyondspring (NASDAQ:BYSI) has been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Beyondspring earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.9863738693475 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Beyondspring (NASDAQ BYSI) opened at $30.04 on Thursday. The stock has a market capitalization of $744.29 and a PE ratio of -6.75. Beyondspring has a 12-month low of $16.55 and a 12-month high of $48.49.

Beyondspring (NASDAQ:BYSI) last posted its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.01. equities research analysts forecast that Beyondspring will post -4.41 EPS for the current year.

BYSI has been the subject of several recent research reports. Maxim Group reissued a “buy” rating and set a $52.00 price objective on shares of Beyondspring in a report on Friday, October 27th. HC Wainwright set a $60.00 target price on Beyondspring and gave the stock a “buy” rating in a research report on Monday, December 4th. Zacks Investment Research lowered Beyondspring from a “hold” rating to a “sell” rating in a research report on Monday, November 13th. Finally, Seaport Global Securities initiated coverage on Beyondspring in a research report on Tuesday, December 5th. They set a “buy” rating and a $56.00 target price for the company. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $54.50.

TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Beyondspring (BYSI) Share Price” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at

About Beyondspring

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Insider Buying and Selling by Quarter for Beyondspring (NASDAQ:BYSI)

Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit